密爾克衛(603713.SH):演若投資等合計減持157萬股
格隆匯7月21日丨密爾克衛(603713.SH)公佈,接到股東上海演若投資合夥企業(有限合夥)(簡稱“演若投資”)、上海演智投資合夥企業(有限合夥)(簡稱“演智投資”)、上海演惠投資合夥企業(有限合夥)(簡稱“演惠投資”)的通知,演若投資、演智投資、演惠投資於2025年7月21日通過上海證券交易所交易系統以大宗交易方式分別減持公司股份數量713,300股、484,900股、372,600股,即合計減持公司股份1,570,800股,其與一致行動人合計持有公司股份比例由48.03%減少至47.04%,權益變動觸及1%刻度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.